Member Info for Laura2022

Oh..sorry and thanks

He only had 200mln not 330mln ?

My purchases at 0.77p are looking very healthy

Well done everyone so far

Totally agree

I'm glad I purchased some of these a few months ago

Let's see if plays out similar this week as looking back it was this ladt week in August where PYC did a large move

I don't see much value in trying to engage with perpetually negative people

Morning Debull

Many thanks for that correction and subsequent points

Much appreciated

Thanks Banbury, incase being tongue in cheek amd from what I read last year even the lithium photos were "not quite as they seemed" cough cough

But...gold at $2500 so that will help

Zero Oz x $2500 = ???

Hand to mouth

More and more companies being rewarded for using data properly in order to get FDA fast track status, last week was GSK and today FARN

TURKU, Finland - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER-1 receptor targeting approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumors, today announces that their lead candidate bexmarilimab has been granted Fast Track Designation for the treatment of relapsed or refractory myelodysplastic syndrome  (r/r MDS) in combination with azacitidine by the USA Food and Drug Administration (the FDA).

 

Fast Track Designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening disease or conditions, which demonstrate the potential to address an unmet medical need. The designation offers the opportunity for frequent interactions with the FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval, as well as eligibility for rolling submission of a New Drug Application.

Original agreement April 2023

https://www.lse.co.uk/rns/PYC/collaborative-services-agreement-ipr3npyexm51bvv.html

Inaphaea Evaluation and Commercial Use Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of an Evaluation and Commercial Use agreement ("Agreement") with Swedish contract research organisation BioReperia AB ("BioReperia") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and commercial use in BioReperia's unique in-vivo ZTX® platform. The contract initially focusses on establishment of up to four glioblastoma zebrafish xenografts which will then be offered for commercial services by BioReperia. Additional PDCs across Inaphaea's range of 66 cancer types can be added at any time.

Inaphaea will be entitled to an upfront fee and a percentage of service royalties on commercialisation of the models. Both companies have also agreed to co-market their respective services. The Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

Inaphaea Evaluation and Commercial Use Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of an Evaluation and Commercial Use agreement ("Agreement") with Swedish contract research organisation BioReperia AB ("BioReperia") to provide Inaphaea's Patient Derived Cells ("PDC") for evaluation and commercial use in BioReperia's unique in-vivo ZTX® platform. The contract initially focusses on establishment of up to four glioblastoma zebrafish xenografts which will then be offered for commercial services by BioReperia. Additional PDCs across Inaphaea's range of 66 cancer types can be added at any time.

Inaphaea will be entitled to an upfront fee and a percentage of service royalties on commercialisation of the models. Both companies have also agreed to co-market their respective services. The Agreement is for a period of 12 months initially and may be extended in writing by mutual agreement.

But CRCL (RGM and it's other guises) have been abject failures over 10yrs ?

Good point you've made there Iano

I purchased some on Friday

I remain extremely optimistic about our future, and believe that the Company continues to be significantly undervalued. As such the Board are actively working to understand the benefits and requirements of listing Audioboom in the US in order to increase the valuation of the business, as well as assessing transactional opportunities to give the Company greater scale. I would like to express my appreciation to the Audioboom team for building our business so efficiently, and to thank shareholders for their continued support and belief in the future of the Company."

I assume they've done it because otherwise they lose EVERYTHING

I.e they keep rolling over the debt on the off chance something happens to help them crystallise their investment

To them it's better to keep the donkey going ?

Thereshegoes

I mentioned 2mths ago how us small fry need people like yiu to try to help when AIM BODs get rotten

So sorry to hear of your personal situations

Truly hope it comes better for you

L

X